Daré Bioscience EBITDA 2011-2026 | DARE

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Daré Bioscience

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-11.9 M	-23.4 M	-30.9 M	-31.4 M	-39 M	-27.4 B	-14.3 M	-11.7 M	-3.69 M	-36.9 M	-37 M	-20.2 M	-15.7 M	-21.2 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-3.69 M	-27.4 B	-1.98 B

Quarterly EBITDA Daré Bioscience

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-4.42 M	-	-	-	-6.01 M	-	-	-	-8.37 M	-	-7.13 M	395 K	-8.4 M	-	-12.6 M	-9.15 M	-7.69 M	-	-7.55 M	-7.1 M	-4.24 M	-	-3.42 M	-3.98 M	-3.08 M	-	-2.62 M	-3.62 M	-7.68 M	-	-1.33 M	-480 K	-162 K	-	-5.96 K	-241 K	61 K	-	129 K	83 K	41 K	-	93 K	63 K	36 K	-	163 K	121 K	71 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
395 K	-12.6 M	-3.27 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.85	3.22 %	$ 9.26 B	Australia
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 330.55	-0.85 %	$ 43.3 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aligos Therapeutics ALGS	-87.1 M	$ 7.51	1.21 %	$ 74.2 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 21.68	-	$ 1.01 B	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
BioNTech SE BNTX	15.3 B	$ 99.49	0.02 %	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Burford Capital Limited BUR	242 M	$ 4.79	1.06 %	$ 771 M	Britain
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Cabaletta Bio CABA	-171 M	$ 3.46	1.62 %	$ 348 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 3.17	-2.16 %	$ 5.22 M	Israel
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
ContraFect Corporation CFRX	-64.5 M	-	-5.16 %	$ 5.39 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	24.8 M	$ 1.5	-3.23 %	$ 386 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.24	-0.12 %	$ 453 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.54	-0.18 %	$ 3.12 B	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.48	-1.01 %	$ 394 M	Britain
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-22.2 M	-	-16.75 %	$ 25.8 M	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Clearside Biomedical CLSD	-24.8 M	-	-	$ 25.3 M	USA
Celldex Therapeutics CLDX	-284 M	$ 33.97	0.3 %	$ 2.26 B	USA
bluebird bio BLUE	-216 M	-	-	$ 546 M	USA
CNS Pharmaceuticals CNSP	-16 M	$ 2.67	-2.91 %	$ 1.18 M	USA
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain